. Author manuscript; available in PMC: 2021 Sep 9.

Published in final edited form as: Lancet Oncol. 2020 Oct 6;21(11):1433–1442. doi: 10.1016/S1470-2045(20)30441-1

Table 2:

Tumour response by EZH2 mutation status in the modified intention-to-treat population as assessed by the IRC and investigators

	EZH2^mut (n=45)		EZH2^WT (n=54)
	IRC-assessed	Investigator-assessed	IRC-assessed	Investigator-assessed
Objective response rate^*	31 (69%; 53–82)	35 (78%; 63–89)	19 (35%; 23–49)	18 (33%; 21–48)
Overall disease control rate^†	44 (98%)	45 (100%)	37 (69%)	34 (63%)
Best overall response
Complete response	6 (13%)	4 (9%)	2 (4%)	3 (6%)
Partial response	25 (56%)	31 (69%)	17 (31%)	15 (28%)
Stable disease	13 (29%)	10 (22%)	18 (33%)	16 (30%)
Progressive disease	1 (2%)	0	12 (22%)	16 (30%)
Not estimable or unknown	0	0	5 (9%)	4 (7%)

Data are n (%; 95% CI) or n (%). IRC=independent radiology committee.

Objective response rate includes patients with a complete or partial response.

^†

Overall disease control rate includes patients with a complete response, partial response, or stable disease.